Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)(☆)

por Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., Morland, B., Rossig, C., Canete Nieto, A., Longhi, A., Lervat, C., Entz-Werle, N., Strauss, S.J., Marec-Berard, P., Okpara, C.E., He, C., Dutta, L., Casanova, M.
Publicado 2021

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

por Doz, François, van Tilburg, Cornelis M, Geoerger, Birgit, Højgaard, Martin, Øra, Ingrid, Boni, Valentina, Capra, Michael, Chisholm, Julia, Chung, Hyun Cheol, DuBois, Steven G, Gallego-Melcon, Soledad, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Hong, David S, Italiano, Antoine, Kang, Hyoung Jin, Nysom, Karsten, Thorwarth, Anne, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Gavrilovic, Igor T, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, Drilon, Alexander, Perreault, Sebastien
Publicado 2021